Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, Novo Nordisk sues Eli Lilly over GLP-1 advertising it calls misleading, President Trump announces a phased tariff plan for imported generic drugs, and a new commentary argues pharma's AI investment is missing the areas of drug discovery where it matters most. President Trump has announced a phased tariff plan for imported generic drugs, starting at zero through August 2026 before rising to 100 percent in 2028 and 200 percent in 2029. India, which supplies nearly half of the generic drugs used in the U.S., is seen as most exposed, alongside China's dominant role in supplying active pharmaceutical ingredients. Thanks for listening to Pharmaceutical Executive Daily.